Beta Bionics (NASDAQ:BBNX) Trading Up 8.3% - What's Next?

Key Points

• Beta Bionics shares jumped about 8.3% to $11.51 on Tuesday, but trading was thin — roughly 85,358 shares changed hands, down about 93% from the ~1.24 million average daily volume.
• Analysts carry a consensus Moderate Buy rating with a $22.70 price target, though recent notes include Bank of America downgrading to neutral and Goldman Sachs trimming its price objective from $23 to $20.
• The company beat quarterly EPS expectations (loss of $0.30 vs. -$0.42) on $32.12 million in revenue but remains unprofitable (net margin -73%), has a $513 million market cap and high volatility (beta 5.06), while institutional investors such as Vanguard have significantly increased positions.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) rose 8.3% on Tuesday . The stock traded as high as $11.37 and last traded at $11.51. Approximately 85,358 shares were traded during trading, a decline of 93% from the average daily volume of 1,242,447 shares. The stock had previously closed at $10.63.

Analyst Upgrades and Downgrades

A number of analysts recently commented on BBNX shares. Bank of America lowered Beta Bionics from a "buy" rating to a "neutral" rating in a research report on Friday, January 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Beta Bionics in a research report on Friday, March 27th. Wall Street Zen cut Beta Bionics from a "hold" rating to a "sell" rating in a report on Sunday, March 29th. Lake Street Capital set a $20.00 price target on shares of Beta Bionics in a research note on Wednesday, February 18th. Finally, The Goldman Sachs Group lowered their price objective on shares of Beta Bionics from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.70.

Beta Bionics Trading Up 8.8%

The stock has a market capitalization of $513.28 million, a P/E ratio of -5.92 and a beta of 5.06. The business has a fifty day simple moving average of $11.76 and a 200 day simple moving average of $20.31.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, beating analysts' consensus estimates of ($0.42) by $0.12. Beta Bionics had a negative return on equity of 20.29% and a negative net margin of 73.02%.The company had revenue of $32.12 million for the quarter.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BBNX. Vanguard Group Inc. increased its stake in Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company's stock valued at $44,036,000 after buying an additional 1,509,217 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Beta Bionics during the fourth quarter valued at approximately $40,437,000. Eversept Partners LP bought a new stake in Beta Bionics during the fourth quarter worth $20,667,000. 12 West Capital Management LP bought a new position in Beta Bionics in the 4th quarter valued at $17,520,000. Finally, Soleus Capital Management L.P. increased its position in shares of Beta Bionics by 12.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company's stock valued at $55,622,000 after purchasing an additional 424,817 shares during the last quarter.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company's flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics' offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.